Towards Healthcare
Chronic Obstructive Pulmonary Disease Market
Updated Date: 14 January 2026   |   Report Code: 5154
sales@towardshealthcare.com +1 804-441-9344
Download Sample Order Now

Chronic Obstructive Pulmonary Disease (COPD) Market Supports Healthcare Infrastructure Growth

Based on market forecasts, the chronic obstructive pulmonary disease sector will expand from USD 23.55 billion in 2025 to USD 36.29 billion by 2035, experiencing a CAGR of 4.42%. In 2023, North America led the COPD market, with chronic bronchitis and drug treatments taking the top spots. Hospitals and clinics were the key end users. Looking ahead, Asia Pacific and oxygen therapy are expected to see the fastest growth.

Last Updated : 14 January 2026 Category: Therapeutic Area Insight Code: 5154 Format: PDF / PPT / Excel

Content

Introduction

  • Research Objective
  • Scope of the Study
  • Definition and Taxonomy

Research Methodology

  • Research Approach
  • Data Sources
  • Assumptions

Executive Summary

  • Synopsis
  • Analyst Recommendations

Market Overview 

  • Market Dynamics
    • Market Drivers
    • Market Restraints
    • Market Opportunities
  • Value Chain Analysis
    • Raw Material Sourcing
    • Manufacturing Process
    • Logistics & Transportation
    • Buyer Preferences
  • Trends
    • Market Trends
    • Technological Trends
  • Porter’s Five Forces Analysis
    • Bargaining Power of Suppliers
    • Bargaining Power of Buyers
    • Threat of Substitute
    • Threat of New Entrants
    • Degree of Competition
  • PESTLE Analysis for 5 Leading Countries
    • Regulatory Framework for Leading Countries/Regions
    • Supply Demand Analysis
    • Production & Consumption Statistics
    • Export Import Statistics
    • Price Trend Analysis

Global Chronic Obstructive Pulmonary Disease Market Assessment

  • Overview
  • Global Chronic Obstructive Pulmonary Disease Market Size Value (US$) and Volume (Billion Tons), by Disease Type (2021 – 2033)
    • Emphysema
    • Chronic Bronchitis
  • Global Chronic Obstructive Pulmonary Disease Market Size Value (US$) and Volume (Billion Tons), by Treatment Type (2021 – 2033)
    • Drugs 
      • Bronchodilator Monotherapy
      • Short-Acting Beta2-Agonists (SABAs)
      • Long-Acting Beta2-Agonists (LABAs)
      • Anti-Inflammatory Drugs
      • Oral And Inhaled Corticosteroids
      • Anti-Leukotrienes
    • Surgery 
      • Lung Volume Reduction Surgery (LVRS)
      • Lung Transplant
      • Bullectomy
      • Others
    • Oxygen Therapy
  • Global Chronic Obstructive Pulmonary Disease Market Size Value (US$) and Volume (Billion Tons), by End User Type (2021 – 2033)
    • Hospitals & Clinics
    • Homecare Settings
    • Others
  • Global Chronic Obstructive Pulmonary Disease Market Size Value (US$) and Volume (Billion Tons), by Region (2021 – 2033)
    • North America
      • U.S.
      • Canada
    • Europe
      • Germany
      • France
      • UK
      • Italy
      • Spain
      • Rest of Europe
    • Asia-Pacific 
      • China
      • Japan
      • India
      • South Korea
      • Rest of Asia-Pacific
    • Rest of the World

North America Chronic Obstructive Pulmonary Disease Market Assessment

  • Overview
  • Global Chronic Obstructive Pulmonary Disease Market Size Value (US$) and Volume (Billion Tons), by Disease Type (2021 – 2033)
    • Emphysema
    • Chronic Bronchitis
  • North America Chronic Obstructive Pulmonary Disease Market Size Value (US$) and Volume (Billion Tons), by Treatment Type (2021 – 2033)
    • Drugs 
      • Bronchodilator Monotherapy
      • Short-Acting Beta2-Agonists (SABAs)
      • Long-Acting Beta2-Agonists (LABAs)
      • Anti-Inflammatory Drugs
      • Oral And Inhaled Corticosteroids
      • Anti-Leukotrienes
    • Surgery 
      • Lung Volume Reduction Surgery (LVRS)
      • Lung Transplant
      • Bullectomy
      • Others
    • Oxygen Therapy
  • North America Chronic Obstructive Pulmonary Disease Market Size Value (US$) and Volume (Billion Tons), by End User Type (2021 – 2033)
    • Hospitals & Clinics
    • Homecare Settings
    • Others
  • North America Chronic Obstructive Pulmonary Disease Market Size Value (US$) and Volume (Billion Tons), by Country Type (2021 – 2033)
    • U.S.
    • Canada

Europe Chronic Obstructive Pulmonary Disease Market Assessment

  • Overview
  • Europe Chronic Obstructive Pulmonary Disease Market Size Value (US$) and Volume (Billion Tons), by Disease Type (2021 – 2033)
    • Emphysema
    • Chronic Bronchitis
  • Europe Chronic Obstructive Pulmonary Disease Market Size Value (US$) and Volume (Billion Tons), by Treatment Type (2021 – 2033)
    • Drugs 
      • Bronchodilator Monotherapy
      • Short-Acting Beta2-Agonists (SABAs)
      • Long-Acting Beta2-Agonists (LABAs)
      • Anti-Inflammatory Drugs
      • Oral And Inhaled Corticosteroids
      • Anti-Leukotrienes
    • Surgery 
      • Lung Volume Reduction Surgery (LVRS)
      • Lung Transplant
      • Bullectomy
      • Others
    • Oxygen Therapy
  • Europe Chronic Obstructive Pulmonary Disease Market Size Value (US$) and Volume (Billion Tons), by End User Type (2021 – 2033)
    • Hospitals & Clinics
    • Homecare Settings
    • Others
  • Europe Chronic Obstructive Pulmonary Disease Market Size Value (US$) and Volume (Billion Tons), by Country Type (2021 – 2033)
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe

Asia-Pacific Chronic Obstructive Pulmonary Disease Market Assessment

  • Overview
  • Asia-Pacific Chronic Obstructive Pulmonary Disease Market Size Value (US$) and Volume (Billion Tons), by Disease Type (2021 – 2033)
    • Emphysema
    • Chronic Bronchitis
  • Asia-Pacific Chronic Obstructive Pulmonary Disease Market Size Value (US$) and Volume (Billion Tons), by Treatment Type (2021 – 2033)
    • Drugs 
      • Bronchodilator Monotherapy
      • Short-Acting Beta2-Agonists (SABAs)
      • Long-Acting Beta2-Agonists (LABAs)
      • Anti-Inflammatory Drugs
      • Oral And Inhaled Corticosteroids
      • Anti-Leukotrienes
    • Surgery 
      • Lung Volume Reduction Surgery (LVRS)
      • Lung Transplant
      • Bullectomy
      • Others
    • Oxygen Therapy
  • Asia-Pacific Chronic Obstructive Pulmonary Disease Market Size Value (US$) and Volume (Billion Tons), by End User Type (2021 – 2033)
    • Hospitals & Clinics
    • Homecare Settings
    • Others
  • Asia-Pacific Chronic Obstructive Pulmonary Disease Market Size Value (US$) and Volume (Billion Tons), by Country Type (2021 – 2033)
    • China
    • Japan
    • India
    • South Korea
    • Rest of Asia-Pacific

Rest of the World Chronic Obstructive Pulmonary Disease Market Assessment

  • Overview
  • Rest of the World Chronic Obstructive Pulmonary Disease Market Size Value (US$) and Volume (Billion Tons), by Disease Type (2021 – 2033)
    • Emphysema
    • Chronic Bronchitis
  • Rest of the World Chronic Obstructive Pulmonary Disease Market Size Value (US$) and Volume (Billion Tons), by Treatment Type (2021 – 2033)
    • Drugs 
      • Bronchodilator Monotherapy
      • Short-Acting Beta2-Agonists (SABAs)
      • Long-Acting Beta2-Agonists (LABAs)
      • Anti-Inflammatory Drugs
      • Oral And Inhaled Corticosteroids
      • Anti-Leukotrienes
    • Surgery 
      • Lung Volume Reduction Surgery (LVRS)
      • Lung Transplant
      • Bullectomy
      • Others
    • Oxygen Therapy
  • Rest of the World Chronic Obstructive Pulmonary Disease Market Size Value (US$) and Volume (Billion Tons), by End User Type (2021 – 2033)
    • Hospitals & Clinics
    • Homecare Settings
    • Others

Company Profiles

  • Almirall
    • Company Overview
    • Geographic Footprints
    • Financial Performance
    • Product Portfolio
    • SWOT Analysis
    • R&D Efforts
    • Recent Developments & Strategic Collaborations
      • Product Launch/M&A/Technical Collaboration
  • Abbott Laboratories
  • Dr. Reddy’s Laboratories Ltd.
  • AstraZeneca
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline
  • Boehringer Ingelheim
  • Pfizer Inc.
  • Astellas Pharma
  • Novartis AG
  • Merck & Co., Inc.

Conclusion & Recommendations

FAQ's

Answer : The COPD market is expected to grow from USD 23.55 billion in 2025 to USD 36.29 billion by 2035, registering a steady CAGR of 4.42% driven by rising disease prevalence and long-term treatment demand.

Answer : North America leads the market due to high COPD prevalence, strong healthcare infrastructure, early diagnosis initiatives, high treatment adoption, and substantial healthcare spending in the U.S. and Canada.

Answer : Major companies such as AstraZeneca, GSK, Pfizer, Novartis, Merck & Co., Roche, and Boehringer Ingelheim are driving market innovation through robust pipelines, biologics, and next-generation inhaled therapies.
Any Questions

Meet the Team

Deepa Pandey is a focused and detail-oriented market research professional with growing expertise in the healthcare sector, delivering high-quality insights across therapeutic areas, diagnostics, biotechnology and healthcare services.

Learn more about Deepa Pandey

Aditi Shivarkar is a seasoned professional with over 14 years of experience in healthcare market research. As a content reviewer, Aditi ensures the quality and accuracy of all market insights and data presented by the research team.

Learn more about Aditi Shivarkar